AstraZeneca to Present Overall Survival Data From Four Pivotal Phase III Trials in Presidential Symposia at ESMO 2026 Featuring Sone-Ve, Imfinzi, Tagrisso and Savolitinib
October 20, 2026
October 20, 2026
WILMINGTON, Delaware, Oct. 20 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI(R) (durvalumab), TAGRISSO(R) (osimertinib) and savolitinib
19 October 2026
CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of . . .
* * *
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI(R) (durvalumab), TAGRISSO(R) (osimertinib) and savolitinib
19 October 2026
CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of . . .